Compare Adaptive Biotechnologies Corp (ADPT) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Vanguard Total International Stock Index Fund ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.04 (market cap $3.33B), while Vanguard Total International Stock Index Fund ETF trades at $84.2. Which is the better fit depends on your goals.
| ADPT | VXUS | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Sector/Thematic |
52-Week High | $22.37 | $87.06 |
52-Week Low | $10.24 | $68.24 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
VXUS trades at $86.17, up 1.57% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF provides diversified international equity exposure across developed and emerging markets, holding over 8,700 stocks. Recent news highlights its role in portfolio diversification amid high U.S. valuations, with Vanguard surpassing iShares as the largest ETF provider in June 2026.
VXUS offers a strategic hedge against U.S. market concentration, trading at a discount to domestic peers. Key risks include currency fluctuations, geopolitical tensions, and emerging market volatility. Analyst sentiment is positive due to broad diversification and cost efficiency, though performance depends on global economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
